Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro. References: Leiva MC, Ortiz R, Contreras-Cáceres R, Perazzoli G, Mayevych I, López-Romero JM, Sarabia F, Baeyens JM, Melguizo C, Prados J. Tripalmitin nanoparticle formulations significantly enhance paclitaxel antitumor activity against breast and lung cancer cells in vitro. Sci Rep. 2017 Oct 18;7(1):13506. doi: 10.1038/s41598-017-13816-z. PubMed PMID: 29044153; PubMed Central PMCID: PMC5647375.

纯度：≥98%

CAS：555-44-2